Amarin Corp. (AMRN) Tops Q1 EPS by 6c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amarin Corp. (AMRN) Reports Licensee HLS Therapeutics Inc. Files NDA for Vascepa with Health Canada
April 29, 2019 6:09 AM EDTAmarin Corporation plc (NASDAQ: AMRN) today announced that its licensee in Canada, HLS Therapeutics Inc. (HLS), has filed a New Drug Submission (NDS) with Health Canada for Vascepa® (icosapent ethyl) capsules. The NDS seeks an indication for promotion of Vascepa in Canada to reduce the risk of major adverse cardiovascular events (MACE) in statin-treated patients with elevated triglycerides and other risk factors. This is the first submission of Vascepa to Health Canada for any indication and, if approved, Vascepa will be the first drug approved in Canada for this important indication.
As previously... More
